FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208130999> ?p ?o ?g. }

• W3208130999 endingPage "S320" @default.
• W3208130999 startingPage "S319" @default.
• W3208130999 abstract "Introduction: Inflammatory Bowel Disease (IBD) treatment has changed significantly over the past decade with biologics initiated earlier. Recent data suggest that early initiation of biologics could be more beneficial to patients. Our study investigates the trends of utilization of biologics as a first line therapy agents in the management of both Crohn’s Disease (CD) and Ulcerative Colitis (UC) patients from 2010 to 2020. Methods: We used a commercial database (Explorys Inc, Cleveland, OH) which includes electronic health record data from 26 major integrated US healthcare systems. Based on Systematized Nomenclature Of Medicine – Clinical Terms (SNOMED-CT), we identified all patients (age >18 years) who were diagnosed with either CD or UC between 2010 and 2020 and then treated with any type of biologics as a first line agent. The biologic group included Adalimumab, Certolizumab pegol, Golimumab, Infliximab, Natalizumab, Ustekinumab & Vedolizumab. We did not exclude patients who were received corticosteroids. Results: Of the 59,936,800 individuals in the database from 2010 to 2020. We identified 182,310 (0.30%) patients with CD and 148,300 (0.25%) patients with UC, of which 20,790 (11.4%) and 10,400 (7.0%) patients received biologics as a first line therapy, respectively. The utilization of biologics as first line therapy in the management of CD progressively increased from 4.9% in 2010 to 13.7% in 2020. Similarly, the utilization of biologics as first line therapy in the management of UC progressively increased from 2.0% in 2010 to 7.3% in 2020. Overall, patients with CD were 1.71 times more likely to be started on biologics as a first line therapy compared to patients with ulcerative colitis (CI 1.67 - 1.75, < 0.0001). Furthermore, Infliximab was the biologic agent of choice in both CD and UC accounting for 40.5% of all biologics. Conclusion: This is the largest individual study investigating the trends of utilization of biologics as first line therapy agents in inflammatory bowel disease. Our findings suggest a possible paradigm shift in IBD management as we found that patients with inflammatory bowel disease are increasingly more likely to be treated with a biologic agent as a first line therapy. Furthermore, patients with Crohn’s Disease patients were significantly more likely to receive biologics as first line therapy compared to patients with Ulcerative Colitis.Figure 1.: Clinical Remission and Response Over Time *P ≤ .05, **P ≤ .01, ***P ≤ .001 vs PBO. Clinical remission per CDAI criterion: CDAI < 150 Clinical remission per SF/AP criteria: average daily SF ≤ 2.8 and not worse than baseline plus average daily AP score ≤ 1 and not worse than baseline. Clinical response per CDAI criterion: ≥ 100-point decrease from baseline in CDAI. Clinical response per SF/AP criteria: ≥ 30% decrease in average daily SF and/or ≥ 30% decrease in average daily AP and both not worse than baseline. AP, abdominal pain; CDAI, Crohn's Disease Activity Index; PBO, placebo; SF, stool frequency; RZB, risankizumab.Table 1.: Demographics and Pre and Post Admission Medical Therapy." @default.
• W3208130999 created "2021-11-08" @default.
• W3208130999 creator A5008523059 @default.
• W3208130999 creator A5032990693 @default.
• W3208130999 creator A5039543953 @default.
• W3208130999 creator A5082987648 @default.
• W3208130999 creator A5089509090 @default.
• W3208130999 date "2021-10-01" @default.
• W3208130999 modified "2023-09-23" @default.
• W3208130999 title "S704 Temporal Trends of Utilization of Biologics as First-Line Therapy in the Management of Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Study" @default.
• W3208130999 doi "https://doi.org/10.14309/01.ajg.0000776348.64683.9e" @default.
• W3208130999 hasPublicationYear "2021" @default.
• W3208130999 type Work @default.
• W3208130999 sameAs 3208130999 @default.
• W3208130999 citedByCount "0" @default.
• W3208130999 crossrefType "journal-article" @default.
• W3208130999 hasAuthorship W3208130999A5008523059 @default.
• W3208130999 hasAuthorship W3208130999A5032990693 @default.
• W3208130999 hasAuthorship W3208130999A5039543953 @default.
• W3208130999 hasAuthorship W3208130999A5082987648 @default.
• W3208130999 hasAuthorship W3208130999A5089509090 @default.
• W3208130999 hasBestOaLocation W32081309991 @default.
• W3208130999 hasConcept C121608353 @default.
• W3208130999 hasConcept C126322002 @default.
• W3208130999 hasConcept C2776207728 @default.
• W3208130999 hasConcept C2776215756 @default.
• W3208130999 hasConcept C2777138892 @default.
• W3208130999 hasConcept C2778260677 @default.
• W3208130999 hasConcept C2778435480 @default.
• W3208130999 hasConcept C2778975655 @default.
• W3208130999 hasConcept C2779134260 @default.
• W3208130999 hasConcept C2779280984 @default.
• W3208130999 hasConcept C2780132546 @default.
• W3208130999 hasConcept C2780479503 @default.
• W3208130999 hasConcept C2781004633 @default.
• W3208130999 hasConcept C2781290027 @default.
• W3208130999 hasConcept C2908647359 @default.
• W3208130999 hasConcept C526805850 @default.
• W3208130999 hasConcept C71924100 @default.
• W3208130999 hasConcept C99454951 @default.
• W3208130999 hasConceptScore W3208130999C121608353 @default.
• W3208130999 hasConceptScore W3208130999C126322002 @default.
• W3208130999 hasConceptScore W3208130999C2776207728 @default.
• W3208130999 hasConceptScore W3208130999C2776215756 @default.
• W3208130999 hasConceptScore W3208130999C2777138892 @default.
• W3208130999 hasConceptScore W3208130999C2778260677 @default.
• W3208130999 hasConceptScore W3208130999C2778435480 @default.
• W3208130999 hasConceptScore W3208130999C2778975655 @default.
• W3208130999 hasConceptScore W3208130999C2779134260 @default.
• W3208130999 hasConceptScore W3208130999C2779280984 @default.
• W3208130999 hasConceptScore W3208130999C2780132546 @default.
• W3208130999 hasConceptScore W3208130999C2780479503 @default.
• W3208130999 hasConceptScore W3208130999C2781004633 @default.
• W3208130999 hasConceptScore W3208130999C2781290027 @default.
• W3208130999 hasConceptScore W3208130999C2908647359 @default.
• W3208130999 hasConceptScore W3208130999C526805850 @default.
• W3208130999 hasConceptScore W3208130999C71924100 @default.
• W3208130999 hasConceptScore W3208130999C99454951 @default.
• W3208130999 hasIssue "1" @default.
• W3208130999 hasLocation W32081309991 @default.
• W3208130999 hasLocation W32081309992 @default.
• W3208130999 hasOpenAccess W3208130999 @default.
• W3208130999 hasPrimaryLocation W32081309991 @default.
• W3208130999 hasRelatedWork W1569284502 @default.
• W3208130999 hasRelatedWork W1964694255 @default.
• W3208130999 hasRelatedWork W2187503363 @default.
• W3208130999 hasRelatedWork W2198790708 @default.
• W3208130999 hasRelatedWork W2414272582 @default.
• W3208130999 hasRelatedWork W2803673833 @default.
• W3208130999 hasRelatedWork W4205369309 @default.
• W3208130999 hasRelatedWork W4242305736 @default.
• W3208130999 hasRelatedWork W4253441736 @default.
• W3208130999 hasRelatedWork W4294044012 @default.
• W3208130999 hasVolume "116" @default.
• W3208130999 isParatext "false" @default.
• W3208130999 isRetracted "false" @default.
• W3208130999 magId "3208130999" @default.
• W3208130999 workType "article" @default.